Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025)

Editas Medicine (EDIT) has disclosed Return on Capital Employed for 10 consecutive years, with 1.38% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 57.0% to 1.38% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.38%, a 57.0% decrease, with the full-year FY2024 number at 0.73%, down 35.0% from a year prior.
  • Return on Capital Employed was 1.38% for Q3 2025 at Editas Medicine, up from 1.4% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.24% in Q1 2021 to a low of 1.4% in Q2 2025.
  • A 5-year average of 0.59% and a median of 0.46% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: increased 14bps in 2021, then plummeted -77bps in 2025.
  • Editas Medicine's Return on Capital Employed stood at 0.3% in 2021, then crashed by -64bps to 0.49% in 2022, then rose by 21bps to 0.39% in 2023, then plummeted by -153bps to 0.98% in 2024, then crashed by -41bps to 1.38% in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Return on Capital Employed are 1.38% (Q3 2025), 1.4% (Q2 2025), and 1.13% (Q1 2025).